Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 and 2. Cancelled.

3 (**Currently Amended**). A recombinant vector comprising a 5' AAV-1 inverted terminal repeat (ITR) and a heterologous nucleic acid for delivery to a cell ~~selected transgene~~, wherein said ITR has the sequence ~~selected from the group~~ consisting of:

~~(a)~~ nt 1 to 143 of SEQ ID NO: 1~~;~~

~~(b) a nucleic acid sequence complementary to (a); and~~

~~(c) a functional fragment of (a) or (b).~~

4 (Original). The recombinant vector according to claim 3, wherein said vector further comprises a 3' AAV-1 ITR.

5 (**Currently Amended**). A recombinant vector comprising a 3' AAV-1 inverted terminal repeat (ITR) and a heterologous nucleic acid for delivery to a cell ~~selected transgene~~, wherein said ITR has the sequence ~~selected from the group consisting~~ of:

~~(a)~~ nt 4576 to 4718 of SEQ ID NO: 1~~;~~

~~(b) a nucleic acid sequence complementary to (a); and~~

~~(c) a functional fragment of (a) or (b).~~

6 (Original). The recombinant vector according to claim 5, wherein said vector further comprises a 5' AAV-1 ITR.

Claims 7 and 8. Cancelled.

9 (Currently Amended). The recombinant vector according to claim 3, wherein said vector further comprises AAV-1 capsid proteins having the sequence of SEQ ID NO: 13, 15 or 17 ~~or functional fragments thereof~~.

10 (Original). The recombinant vector according to claim 3, wherein said vector further comprises adenovirus sequences.

11 (Original). The host cell transduced with a recombinant viral vector according to claim 3.

Claims 12-16. Cancelled.

17 (Original). A composition comprising a recombinant virus having an AAV-1 capsid comprising an AAV-1 protein selected from among AAV-1 vp1 having the amino acid sequence of SEQ ID No: 13; AAV-1 vp2 having the amino acid sequence of SEQ ID NO: 15 and AAV-1 vp3 having the amino acid sequence of SEQ ID NO: 17 and a heterologous molecule which comprises an AAV 5' inverted terminal repeat sequence (ITR), a transgene, and an AAV 3' ITR.

18 **(Currently Amended)**. The composition of claim 17 wherein the AAV-1 protein vp1 is encoded by a nucleic acid having at least ~~about~~ 98% identity to nucleotides 2223-4431 of SEQ ID NO:1, as measured by ~~MacVector 6.0~~ MACVECTOR 6.0™ program at default parameters.

19 (**Currently Amended**). The composition of claim 17 wherein the AAV-1 protein vp2 is encoded by a nucleic acid having at least ~~about~~ 98% identity to nucleotides 2634-4432 of SEQ ID NO:1, as measured by ~~MacVector 6.0~~ MACVECTOR 6.0™ program at default parameters.

20 (**Currently Amended**). The composition of claim 17 wherein the AAV-1 protein vp3 is encoded by a nucleic acid having at least about 98% identity to nucleotides 2829-4432 of SEQ ID NO:1, as measured by ~~MacVector 6.0~~ MACVECTOR 6.0™ program at default parameters.

21 (Original). The composition of claim 17 wherein the AAV 5' ITR and 3' ITR are of AAV serotype 2.

22 (Original). The composition of claim 21 wherein the recombinant virus further comprises a regulatable promoter which directs expression of the transgene.